Cytokinetics Inc.

Cytokinetics is a late-stage biopharmaceutical company focused on the discovery and development of muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company is also conducting earlier-stage research directed to other compounds with the potential to modulate muscle contractility and other muscle functions. The company's drug candidates in clinical development are omecamtiv mecarbil, a cardiac myosin activator, and reldesemtiv, a fast skeletal muscle troponin activator with orphan drug designation from FDA for the potential treatment of spinal muscular atrophy.
  • TickerCYTK
  • ISINUS23282W6057
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • Homebuilders continue to be leadership. (ex. MTH, PHM, and MHO) • A number of Transportation Sector names are staging price and RS reversals, or remain leadership. (ex. XPO, JBLU, UAL, SKYW, AAL, DAL, UNP, JBHT, KNX, ODFL, LSTR, and SAIA) • Many Materials Sector names appear to be staging price and RS reversals. (ex. DOW, VVV, LYB, MLM, VMC, USCR, EMN, and CMC. )

ValuEngine Rating and Forecast Report for CYTK

ValuEngine Rating and Forecast Report for CYTK

ValuEngine Rating and Forecast Report for CYTK

ValuEngine Rating and Forecast Report for CYTK

A director sold after exercising options/sold 4,260 shares at 12.942USD and

A director at Cytokinetics Inc sold after exercising options/sold 4,260 shares at 12.942USD and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under ...

ValuEngine Rating and Forecast Report for CYTK

ValuEngine Rating and Forecast Report for CYTK

ValuEngine Rating and Forecast Report for CYTK

ValuEngine Rating and Forecast Report for CYTK

ValuEngine Rating and Forecast Report for CYTK

ValuEngine Rating and Forecast Report for CYTK

ValuEngine Rating and Forecast Report for CYTK

ValuEngine Rating and Forecast Report for CYTK

Increased risk weighs on CYTOKINETICS INCO., penalising its rating down to Slightly Negative

The independent financial analyst theScreener just lowered the general evaluation of CYTOKINETICS INCO. (US), active in the Biotechnology industry. As regards its fundamental valuation, the title still shows 1 out of 4 possible stars. Its market behaviour, however, has slightly deteriorated and will be qualified as risky moving forward. theScreener considers that these new qualifications justify an overall rating downgrade to Slightly Negative. As of the analysis date June 14, 2019, the closing price was USD 9.54 and its target price was estimated at USD 6.46.

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • Homebuilders continue to be leadership. (ex. MTH, PHM, and MHO) • A number of Transportation Sector names are staging price and RS reversals, or remain leadership. (ex. XPO, JBLU, UAL, SKYW, AAL, DAL, UNP, JBHT, KNX, ODFL, LSTR, and SAIA) • Many Materials Sector names appear to be staging price and RS reversals. (ex. DOW, VVV, LYB, MLM, VMC, USCR, EMN, and CMC. )

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • A few Consumer Discretionary names continue to act well. (ex. UA, WHR, ELY, RRGB, SHAK, BOOT, ROST, WSM, and COTY) • The decline in oil prices may be helping some of the airlines. A few of them are near potential reversal points (ex. AAL and UAL) • Attractive Technology names include: (ex. UCTT, SEDG, FSLR, and TTEC)

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

• Offshore oil drillers continue to develop positively. Long-term trends are attractive. • Basic Materials are breaking down. The Sector is hitting a new RS lows. • The Financial Sector is also showing a sign of weakness as the RS is also hitting a new 52-week low. Not a good sign for the overall market.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch